Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1 Gliosarcoma 1 Glioblastoma 1

Interventions

Cytarabine 25 Azacitidine 17 fludarabine phosphate 15 fludarabine 15 Cyclophosphamide 14 venetoclax 8 Peripheral Blood Stem Cell Transplantation 8 Methotrexate 8 Busulfan 8 Granulocyte Colony-Stimulating Factor 7 Filgrastim 7 Whole-Body Irradiation 6 Decitabine 6 Cyclosporine 6 Injections 5 Idarubicin 5 decitabine and cedazuridine drug combination 4 Tacrolimus 4 Radiotherapy 4 Mycophenolic Acid 4 Mitoxantrone 4 Daunorubicin 4 Cladribine 4 CPX-351 4 Biopsy 4 midostaurin 3 merphos 3 magrolimab 3 gilteritinib 3 Stem Cell Transplantation 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Leukemia, Myeloid, Acute × ficlatuzumab × Clear all

NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡